Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 46

1.

Zebrafish and Medaka: new model organisms for modern biomedical research.

Lin CY, Chiang CY, Tsai HJ.

J Biomed Sci. 2016 Jan 28;23:19. doi: 10.1186/s12929-016-0236-5. Review.

2.

The Challenge of t (6;9) and FLT3-Positive Acute Myelogenous Leukemia in a Young Adult.

Song Y, Bixby D, Roulston D, Magenau J, Choi SW.

J Leuk (Los Angel). 2014;2. pii: 1000167.

3.

Novel agents for the treatment of childhood acute leukemia.

Annesley CE, Brown P.

Ther Adv Hematol. 2015 Apr;6(2):61-79. doi: 10.1177/2040620714565963. Review.

4.

The Biology and Targeting of FLT3 in Pediatric Leukemia.

Annesley CE, Brown P.

Front Oncol. 2014 Sep 23;4:263. doi: 10.3389/fonc.2014.00263. Review.

5.

Low expression of T-cell transcription factor BCL11b predicts inferior survival in adult standard risk T-cell acute lymphoblastic leukemia patients.

Bartram I, Gökbuget N, Schlee C, Heesch S, Fransecky L, Schwartz S, Stuhlmann R, Schäfer-Eckhart K, Starck M, Reichle A, Hoelzer D, Baldus CD, Neumann M.

J Hematol Oncol. 2014 Jul 15;7:51. doi: 10.1186/s13045-014-0051-y.

6.

The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond.

Wander SA, Levis MJ, Fathi AT.

Ther Adv Hematol. 2014 Jun;5(3):65-77. doi: 10.1177/2040620714532123. Review.

7.

Frequency and Prognostic Relevance of FLT3 Mutations in Saudi Acute Myeloid Leukemia Patients.

Elyamany G, Awad M, Fadalla K, Albalawi M, Al Shahrani M, Al Abdulaaly A.

Adv Hematol. 2014;2014:141360. doi: 10.1155/2014/141360.

8.

Functions of flt3 in zebrafish hematopoiesis and its relevance to human acute myeloid leukemia.

He BL, Shi X, Man CH, Ma AC, Ekker SC, Chow HC, So CW, Choi WW, Zhang W, Zhang Y, Leung AY.

Blood. 2014 Apr 17;123(16):2518-29. doi: 10.1182/blood-2013-02-486688.

9.

Will FLT3 inhibitors fulfill their promise in acute meyloid leukemia?

Pratz KW, Luger SM.

Curr Opin Hematol. 2014 Mar;21(2):72-8. doi: 10.1097/MOH.0000000000000022. Review.

10.

TTT-3002 is a novel FLT3 tyrosine kinase inhibitor with activity against FLT3-associated leukemias in vitro and in vivo.

Ma H, Nguyen B, Li L, Greenblatt S, Williams A, Zhao M, Levis M, Rudek M, Duffield A, Small D.

Blood. 2014 Mar 6;123(10):1525-34. doi: 10.1182/blood-2013-08-523035.

11.

FLT3/D835Y mutation knock-in mice display less aggressive disease compared with FLT3/internal tandem duplication (ITD) mice.

Bailey E, Li L, Duffield AS, Ma HS, Huso DL, Small D.

Proc Natl Acad Sci U S A. 2013 Dec 24;110(52):21113-8. doi: 10.1073/pnas.1310559110.

12.

NPMc+ cooperates with Flt3/ITD mutations to cause acute leukemia recapitulating human disease.

Rau R, Magoon D, Greenblatt S, Li L, Annesley C, Duffield AS, Huso D, McIntyre E, Clohessy JG, Reschke M, Pandolfi PP, Small D, Brown P.

Exp Hematol. 2014 Feb;42(2):101-13.e5. doi: 10.1016/j.exphem.2013.10.005.

13.

TGF-β-Neutralizing Antibody 1D11 Enhances Cytarabine-Induced Apoptosis in AML Cells in the Bone Marrow Microenvironment.

Tabe Y, Shi YX, Zeng Z, Jin L, Shikami M, Hatanaka Y, Miida T, Hsu FJ, Andreeff M, Konopleva M.

PLoS One. 2013 Jun 27;8(6):e62785. doi: 10.1371/journal.pone.0062785.

14.
15.

FLT3/ITD associated with an immature immunophenotype in PML-RARα leukemia.

Takenokuchi M, Kawano S, Nakamachi Y, Sakota Y, Syampurnawati M, Saigo K, Tatsumi E, Kumagai S.

Hematol Rep. 2012 Nov 19;4(4):e22. doi: 10.4081/hr.2012.e22.

16.

Fluvastatin inhibits FLT3 glycosylation in human and murine cells and prolongs survival of mice with FLT3/ITD leukemia.

Williams AB, Li L, Nguyen B, Brown P, Levis M, Small D.

Blood. 2012 Oct 11;120(15):3069-79. doi: 10.1182/blood-2012-01-403493.

17.

Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors.

Williams AB, Nguyen B, Li L, Brown P, Levis M, Leahy D, Small D.

Leukemia. 2013 Jan;27(1):48-55. doi: 10.1038/leu.2012.191.

18.

Treatment of FLT3-ITD acute myeloid leukemia.

Fathi AT, Chen YB.

Am J Blood Res. 2011;1(2):175-89.

19.

Novel vaccine development strategies for inducing mucosal immunity.

Fujkuyama Y, Tokuhara D, Kataoka K, Gilbert RS, McGhee JR, Yuki Y, Kiyono H, Fujihashi K.

Expert Rev Vaccines. 2012 Mar;11(3):367-79. doi: 10.1586/erv.11.196. Review.

20.

Knock-in of a FLT3/ITD mutation cooperates with a NUP98-HOXD13 fusion to generate acute myeloid leukemia in a mouse model.

Greenblatt S, Li L, Slape C, Nguyen B, Novak R, Duffield A, Huso D, Desiderio S, Borowitz MJ, Aplan P, Small D.

Blood. 2012 Mar 22;119(12):2883-94. doi: 10.1182/blood-2011-10-382283.

Supplemental Content

Support Center